ライフサイエンスコーパス: testicular cancer

1 ne years (for chemotherapy to treat advanced testicular cancer).

2 as, cryptorchidism, hypospermatogenesis, and testicular cancer).

3 all common tumour types except leukaemia and testicular cancer.

4 patients without microlithiasis, 38 (8%) had testicular cancer.

5 cceptable toxicity in patients with relapsed testicular cancer.

6 ents had histopathologic correlation; 13 had testicular cancer.

7 from 1.1% for pancreatic cancer to 98.2% for testicular cancer.

8 ed 500 twins with breast cancer and 194 with testicular cancer.

9 r was 37.5 (12.3-115.6) in twins of men with testicular cancer.

10 nts with breast cancer at young ages or with testicular cancer.

11 ders of the male reproductive tract, notably testicular cancer.

12 er childhood cancers, Hodgkin's disease, and testicular cancer.

13 and from patients previously diagnosed with testicular cancer.

14 ys of cisplatin combination chemotherapy for testicular cancer.

15 e multidisciplinary management of metastatic testicular cancer.

16 ding disorders of sexual differentiation and testicular cancer.

17 ug reaction in adult patients with germ cell testicular cancer.

18 d to determine the benefits of screening for testicular cancer.

19 h testicular microlithiasis will not develop testicular cancer.

20 h testicular microlithiasis will not develop testicular cancer.

21 yndrome, which may result in infertility and testicular cancer.

22 nized as late complications of treatment for testicular cancer.

23 will cure 70% of patients with disseminated testicular cancer.

24 med at improving quality of life in men with testicular cancer.

25 the recent clinically relevant literature on testicular cancer.

26 minimization of treatment in good-prognosis testicular cancer.

27 subtypes of acute myelogenous leukemia, and testicular cancer.

28 erative orchiopexy or orchiectomy to prevent testicular cancer.

29 cancer including ovarian, kidney, lung, and testicular cancers.

30 ts had microlithiasis; 13 of these (27%) had testicular cancers.

31 genetic impairment of NER, such as skin and testicular cancers.

32 identified in non-PJS patients with sporadic testicular cancers.

33 .19; 0.17-0.22), melanoma (0.34, 0.27-0.43), testicular cancer (0.47, 0.33-0.67), and endometrial can

34 (35.4 percent), lung cancer (22.5 percent), testicular cancer (14.4 percent), and lymphoma (12.8 per

35 FE rate was greatest for testicular cancer (27.9%), then small-cell lung cancer (

36 ith microlithiasis) patients with a mass had testicular cancer, 43 (10 with microlithiasis) had benig

37 slightly higher lifetime mortality risk from testicular cancer (598 per 100 000; 95% uncertainty inte

38 in African Americans), far more common than testicular cancer (7:100,000).

39 owever, life expectancy loss attributable to testicular cancer (83 days; 95% UI: 42, 124) was more th

40 Anecdotal reports of men developing testicular cancer after previous identification of micro

41 r, and new developments in the management of testicular cancer aimed at improving quality of life in

42 Testicular cancer and infertility affect a similar age g

43 ancers without an apparent age gradient were testicular cancer and mesothelioma.

44 Of 13 patients with testicular cancer and paraneoplastic limbic or brain-ste

45 e fractures, poor sperm quality, and perhaps testicular cancer and rheumatoid arthritis) may yield sp

46 ar with the available treatment regimens for testicular cancer and their associated toxic effects.

47 were more likely to have tumours other than testicular cancer and to develop ataxia, and had a worse

48 e been linked to risk of childhood leukemia, testicular cancer, and breast cancer in the offspring.

49 literature on links between infertility and testicular cancer, and new developments in the managemen

50 17 years or older, diagnosed with germ cell testicular cancer, and previously treated with cisplatin

51 ommon mechanisms involved in infertility and testicular cancer, and scientifically driven evidence-ba

52 and placenta, as well as in prostate cancer, testicular cancer, and uterine cancer.

53 ent of male contraceptives, the treatment of testicular cancers, and ultimately for tissue regenerati

54 er; 487518 due to liver cancer; 13927 due to testicular cancer; and 829396 due to non-Hodgkin lymphom

55 ommon conditions known to be associated with testicular cancer are cryptorchidism, infertility, and o

56 The major pathological types of testicular cancer are seminoma and non-seminomatous germ

57 ithiasis is highly associated with confirmed testicular cancer, as well as with US evidence of testic

58 based treatment recommendations for advanced testicular cancer based on risk stratification.

59 out the management of early non-seminomatous testicular cancer because survival is almost 100% irresp

60 the 11th birthday on three men who developed testicular cancer but, in each, the procedure failed.

61 hat the action of Dnd1Ter was not limited to testicular cancer, but also significantly increased poly

62 in is one of the primary drugs used to treat testicular cancer, but the incidence of significant pulm

63 yptorchism is an established risk factor for testicular cancer, but the role of age at surgical corre

64 In the testicular cancer cell line, NT2, we previously demonstr

65 Ts; (b) elevated expression of Ape1/ref-1 in testicular cancer cell lines results in resistance to ce

66 Re-expression of miR-199a in testicular cancer cells led to suppression of cell growt

67 atin toxicity and reactive oxygen species in testicular cancer cells.

68 The international Testicular Cancer Consortium (TECAC) combined five publi

69 bacute limbic and brain-stem dysfunction and testicular cancer contains antibodies against a protein

70 of 5190 men with GCC who entered the Danish Testicular Cancer database between January 1, 1984, and

71 From the Danish Testicular Cancer database, we identified all patients w

72 Testicular cancer deaths also occurred less frequently t

73 ly curable with cisplatin-based therapy, and testicular cancer-derived human embryonal carcinoma (EC)

74 mon diseases, including male infertility and testicular cancer, due to abnormalities in SSC function.

75 Permanente members, who were diagnosed with testicular cancer during 1973-1996 and who were 15 years

76 we show that fine-mapping of pancreatic and testicular cancer GWAS within one of these loci (Region

77 hile lymphoma, bladder cancer, melanoma, and testicular cancer had lower-than-average ratios.

78 Patients with testicular cancer had the highest sperm retrieval rates

79 Testicular cancer has become a model for a curable neopl

80 g the diagnosis, treatment, and prognosis of testicular cancer have been reported.

81 The aetiologies of breast and testicular cancers have genetic components, for breast c

82 s were positively associated with kidney and testicular cancer [hazard ratio (HR) = 1.10; 95% CI: 0.9

83 nd 1.58 (linear trend test p = 0.18) and for testicular cancer, HRs were 1.0, 1.04, 1.91, 3.17 (linea

84 We analysed risks of breast and testicular cancer in dizygotic twins compared with monoz

85 ages younger than 45 years and with incident testicular cancer in England and Wales during 1971-89 by

86 train 129 males recapitulate many aspects of testicular cancer in human infants and can be used to ev

87 PFOA exposure was associated with kidney and testicular cancer in this population.

88 While the incidence rate of testicular cancer in US White males ages 15-64 years did

89 lar germ cell tumors (TGCT), the most common testicular cancer in young men.

90 In response to a report that testicular cancer incidence in non-Hispanic White males

91 s performed to determine the relationship of testicular cancer, intratesticular mass, and microlithia

92 udies suggest that an increased incidence of testicular cancer is due to a birth-cohort effect and se

93 Testicular cancer is highly curable with cisplatin-based

94 Although testicular cancer is highly treatable and curable, there

95 with low-risk disease is acceptable because testicular cancer is still curable if metastatic recurre

96 Testicular cancer is the most common solid tumor diagnos

97 Testicular cancer is the most common type of cancer in m

98 in 2004 that screening asymptomatic men for testicular cancer is unlikely to produce additional bene

99 ecent advances in diagnosis and treatment of testicular cancer, its causes remain unknown.

100 Children and adolescents with testicular cancer, leukaemia, and Ewing sarcomas are at

101 hormone milieu, leading to the induction of testicular cancer (Leydig cell tumors).

102 elevated Ape1/ref-1 levels observed in human testicular cancer may be related to their relative resis

103 Aetiology of breast and testicular cancers may have prenatal factors, possibly e

104 nical stage (CS) I nonseminomatous germ cell testicular cancer (NSGCT).

105 11th birthday were not at increased risk of testicular cancer (odds ratio = 0.6, 95% CI: 0.08, 5.4).

106 erm cell tumors (GCTs) from 10 patients with testicular cancer of various histologies including semin

107 ober 2007) was also searched using the terms testicular cancer or germ cell tumors.

108 must be maintained, as defects can result in testicular cancer or infertility.

109 resence of cardiovascular disease, diabetes, testicular cancer, or prostate cancer.

110 diagnosis and had lymphoma, acute leukemia, testicular cancer, ovarian cancer, or female breast canc

111 Approximately 50% of these testicular cancer patients will subsequently be cured wi

112 treatment regimen cures 90-95% of metastatic testicular cancer patients.

113 cisplatin-induced ototoxic effects in adult testicular cancer patients.

114 For patients diagnosed with early-stage testicular cancer radical orchidectomy is the primary th

115 All 209 new patients with testicular cancer referred between June 1992 and May 199

116 Testicular cancer remains a major success story in the r

117 Testicular cancer remains a major success story in the r

118 Two genome-wide association studies for testicular cancer report associations at three new loci,

119 Testicular cancer research continues to modify current t

120 Testicular cancers respond favorably to chemotherapy wit

121 , Nanog and Ccnd1, genes with known roles in testicular cancer risk and tumorigenesis, respectively,

122 ssociation of a history of cryptorchism with testicular cancer risk was 4.8 (95% confidence interval

123 her than English on the benefits or harms of testicular cancer screening.

124 , 30 vulvar, 24 ovarian, 20 cervical, and 30 testicular cancer specimens from patients from the Unite

125 solve, with much reliance on using data from testicular cancer studies.

126 rmation on adverse health outcomes (AHOs) in testicular cancer survivors (TCSs) after four cycles of

127 s are an important complication that affects testicular cancer survivors as a consequence of treatmen

128 Health-related issues that confront testicular cancer survivors include the late medical eff

129 Large databases on testicular cancer survivors were analyzed to further def

130 y white men aged 18-55 years into a study of testicular cancer susceptibility conducted in the Philad

131 mors after older radiotherapy strategies for testicular cancer (TC) are well established.

132 ardiovascular disease (CVD) in patients with testicular cancer (TC) given chemotherapy in European st

133 Germ cell testicular cancer (TC) represents a malignancy with high

134 rtant adverse effects after chemotherapy for testicular cancer (TC).

135 tem encephalitis occurs more frequently with testicular cancer than with most other cancers.

136 of 184 consecutive patients with metastatic testicular cancer that had progressed after they receive

137 nd on the benefits or harms of screening for testicular cancer that would affect the USPSTF's previou

138 Despite a high cure rate in patients with testicular cancer, there remain patients in the poor pro

139 he adult-onset disorders low sperm count and testicular cancer, they can constitute a testicular dysg

140 Excellent response of testicular cancer to radiation and chemotherapy results

141 ection, ranging from <1/tumor in thyroid and testicular cancers to >10/tumor in endometrial and color

142 widely accepted strategy in clinical stage I testicular cancer treatment in the community.

143 ere selected based on pertinence to advanced testicular cancer treatment, associated complications, a

144 carcinoma, men undergoing surveillance after testicular cancer treatment, parents of patients treated

145 wo), nasopharyngeal (one), thyroid (one) and testicular cancer (two).

146 ge 40 years in monozygotic twins of men with testicular cancer was 14% (4-46).

147 The relative risk of testicular cancer was 37.5 (12.3-115.6) in twins of men

148 In the early 1970s, metastatic testicular cancer was associated with only 5% survival.

149 The overall risk of testicular cancer was significantly higher in dizygotic

150 expansions underlie some cases of inherited testicular cancer, we also analyzed germline DNA from me

151 of a recent chemotherapy trial for advanced testicular cancer, we discuss the issues that investigat

152 In long-term survivors of testicular cancer, we observed a two-fold or greater ris

153 y losses and lifetime mortality risks due to testicular cancer were compared with life expectancy los

154 August 1992 to April 1998, 65 patients with testicular cancer were treated with high-dose carboplati

155 noma, thyroid cancer, pancreatic cancer, and testicular cancer) were identified among ABOi recipients

156 nsurgical cancers, principally lymphomas and testicular cancer, were few but consistently showed bett

157 on and management of a long-term survivor of testicular cancer who was previously treated with surger

158 5 patients with pathological stage II or III testicular cancer who were treated with platinum-based c

159 veloped to project outcomes in patients with testicular cancer who were undergoing CT surveillance in

160 The largest AOR was for testicular cancer with the very high exposure category [